Hepatite C : características clínicas e biológicas relacionadas às diferentes formas de uso da cocaína by Schuch, Silvia Bassani et al.
APRS Trends Psychiatry Psychother. 2017;39(4) – 285-292
Trends
in Psychiatry and Psychotherapy Review Article
Resumo
Introdução: O vírus da hepatite C (HCV) está relacionado 
com graves patologias hepáticas, como a cirrose e o carcinoma 
hepatocelular, causando mais de meio milhão de mortes todos 
os anos, o que reflete um problema de saúde mundial. Sabe-se 
que usuários de drogas injetáveis possuem alta prevalência de 
infecção pelo HCV, sendo por isso considerados um dos maiores 
grupos de risco. Usuários de cocaína parecem ter maior risco 
de contrair o vírus do que usuários de outras drogas, e diversas 
hipóteses para essa associação estão sendo estudadas.
Objetivo: Revisar evidências de associação da infecção pelo 
HCV em usuários de cocaína, considerando a relevância das 
diferentes formas de administração da droga e comportamentos 
de risco.
Métodos: Esta foi uma revisão narrativa realizada nos principais 
bancos de dados científicos.
Resultados e conclusão: As evidências atuais sugerem que 
o uso de cocaína pode estar associado com a infecção por HCV 
devido às especificidades do padrão de consumo da droga, mesmo 
naqueles indivíduos que não fazem uso de drogas injetáveis, 
além de outros comportamentos de risco, como tatuagens e 
sexo desprotegido. Usuários de cocaína injetável parecem estar 
mais suscetíveis à contaminação do que usuários de cocaína 
não injetável. Entretanto, há a possibilidade de infecção devido 
ao compartilhamento de outros equipamentos de uso além das 
seringas (cachimbos, por exemplo). Além disso, prejuízos do 
sistema imune causados pela cocaína também parecem estar 
associados com a suscetibilidade de infecção pelo HCV, além da 
manutenção e piora dos sintomas da doença.
Descritores: HCV, cocaína, sistema imune, uso de drogas, 
drogas injetáveis, drogas não-injetáveis.
Abstract
Introduction: Hepatitis C virus (HCV) infection is related 
with several liver diseases such as cirrhosis and hepatocellular 
carcinomas, leading to more than 0.5 million deaths every year 
and to a great global burden. It is known that injection drug 
users show a high prevalence of HCV infection, being considered 
a risk group for this disease. Cocaine users seem to be in greater 
risk than other drug users, and several hypotheses for this 
association are being studied. 
Aim: To review data on HCV infection in cocaine users, taking 
into consideration the relevance of the different routes of drug 
administration and other risk behaviors. 
Methods: This was a narrative review performed in the main 
scientific databases.
Results and conclusion: Data suggest that cocaine use could 
be associated with HCV infection due to the specificities of cocaine 
consumption pattern, even in those subjects who do not inject 
drugs, in addition to other risky behaviors, such as tattooing 
and unprotected sex. Injectable cocaine users seem to be more 
susceptible to contamination than users who do not inject drugs. 
However, evidence is pointing to the possibility of infection 
by sharing drug paraphernalia other than syringes. Moreover, 
specific immune system impairments caused by cocaine use are 
also being linked with HCV infection susceptibility, persistence 
and increased pathological effects.
Key words: HCV infection, cocaine, immune system, drug users, 
injection drugs, non-injection drugs.
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Introduction
Current data indicate that approximately 185 
million people worldwide have been infected with 
hepatitis C virus (HCV), and that around 350,000 
deaths occur each year due to all HCV-related causes.1 
HCV infections account for a quarter of the cases of 
cirrhosis and primary liver cancer,2 representing a major 
contribution to end-stage liver disease. Only in Europe, 
estimations via HCV-attributable fractions indicate that 
HCV caused more than 86,000 deaths and 1.2 million 
disability adjusted life years (DALYs) in one year. Most 
of the DALYs (95%) were accumulated by patients in 
preventable disease stages.3
Injection drug users (IDUs) are responsible for a 
major international public health problem, and they 
remain the largest group of persons infected with HCV.4 
Estimates indicate that there are about 16 million 
individuals who inject drugs worldwide,5 and unsafe drug 
paraphernalia is the main agent of virus transmission 
among users. Between 14 and 21 million people (0.3-
0.5% of the population aged 15-64 years) are cocaine 
users.6 Studies suggest that 10 million people who 
inject drugs are HCV-infected worldwide,7 reflecting the 
high prevalence of these comorbidities.
Prevalence of HCV infection among non-injection 
drug users (NIDU), in turn, is much higher than in 
the general population.8,9 HCV infection is more likely 
among older individuals and those with tattoos – factors 
previously associated with HCV infection –, and among 
those who share crack inhalation implements,8 probably 
because of the presence of HCV in intranasal drug users’ 
nasal secretions.10
To facilitate evidence-based policymaking and 
promote better treatments, it is essential to estimate 
the impact of HCV infection in different populations, 
e.g., cocaine users. Our objective is to propose a review 
of HCV infection patterns among cocaine users. For 
that, it is important to understand the immunobiological 
changes that drugs cause in cells compromised by 
hepatitis, differentiate usage patterns and behavior 
among IDUs and NIDUs, and finally propose prevention 
strategies for this group of patients.
HCV and cocaine immune system
It is known that substance use affects several 
components of the immune system. Drug use can affect 
the immune system directly, through the activation 
of receptors on immune cells, or indirectly, acting in 
the central nervous system. This process interferes 
with the immune response mediated by antibodies 
and decreases the production of interleukins (ILs) and 
gamma interferon (IFN-γ). Depending of the type of 
substance, different effects are observed.11 As a result, 
substance use alters host immunity, which is related 
with an increased susceptibility to infections.11,12
Cocaine has multiple physiological and 
pharmacological mechanisms of action that could affect 
immune cell function and response, particularly because 
doses and duration of drug administration are varied. 
Pellegrino et al. showed that peripheral administration 
of cocaine resulted in a significant decrease in mitogen-
induced lymphocyte proliferation.13 Cocaine-induced 
immunomodulation is a complex phenomenon with a 
range of enhancing and inhibitory pathways.14 It acts 
decreasing cytokine formation, lymphocyte proliferation, 
natural killer cell activity, as well as antibody formation 
and cellular hypersensitivity.11 Cocaine also exerts an 
indirect modulation of the immune system through the 
sigma-1 (σ-1) receptor, expressed in the central and 
peripheral nervous system.15
HCV has been shown to bind to the dendritic cell 
immune system, even though viral replication within 
these cells occurs at a very low level. Dendritic cells 
from people with chronic HCV infection are impaired 
in their capacity to stimulate T cells.16 In chronic HCV 
infections, there is a reduction and dysfunction of blood 
dendritic cell subsets.17
There are several lines of evidence demonstrating the 
correlation between substance use and HCV infection. 
Morphine destabilizes IFN-mediated innate immunity 
and enhances HCV replication in human hepatocytes.18,19 
Moreover, recent studies have shown that microRNAs 
(miRNAs) related with the HCV replication promotion 
process are increased in heroin users with HCV infection, 
while HCV-suppressive miRNA are downregulated.20 
New studies have identified cocaine suppression of 
miRNAs associated with HIV infection,21,22 but no 
evidence has been reported regarding HCV infection 
and miRNA modulation by cocaine use so far. Although 
there are several studies investigating substance use 
and HCV, there is a lack of studies that explores the 
specific mechanisms that concern cocaine use and 
HCV infection. Most of the research on cocaine and 
HCV are centered on individuals with HIV and report 
a faster progression to AIDS and decreasing CD4/
CD8 ratio. So far, evidence suggests that cocaine may 
induce suppression in lymphoproliferation by acting on 
receptors located in the periphery, therefore decreasing 
immune defenses and increasing viral load.12,15
HCV core protein promotes proliferation of human 
hepatoma cells via activation of nuclear factor kappa-B 
(NF-κB) – a major, inducible transcription factor 
whose modulation triggers a cascade of intracellular 
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signaling events.23 Cocaine increases the expression 
of NF-κB p105 in mature dendritic cells, which may be 
associated with viral (e.g., HCV or HIV-1) persistence 
or increased pathological effects. Cocaine and HCV may 
act synergistically through their actions in monocyte-
derived mature dendritic cells to interfere with the host’s 
cellular defenses against the virus.24 Such alterations 
could suggest that cocaine use increases susceptibility 
to viral infections.
Few studies have shown alterations in HCV-infected 
cocaine users. We already know that other stimulants, 
such as methamphetamine (METH), inhibit intracellular 
IFN-α expression in human hepatocytes, which was 
associated with the increase in HCV replication. This 
is evidence that METH has the ability to compromise 
IFN-α-mediated innate immunity, thus promoting 
HCV replication in hepatocytes.25 When we consider 
only cocaine, in rats, chronic cocaine administration 
increased IL-10 and TNF-α production and had no effect 
on IL-1 and IFN-γ production.26
Taken together, the poor evidence by immunological 
control of HCV infection and its relationship with a 
stimulant drug like cocaine should lead researchers 
to seek the immunological components that might be 
involved in this association. Questions to address in 
the future include defining in more detail specific HCV-
related cell alterations among cocaine users.
HCV and injecting cocaine use
The most common documented route of HCV 
infection is through blood transfusions without previous 
screening and by sharing syringes among IDUs.27,28 
Therefore, injecting cocaine users, similarly to other 
IDUs, are a major risk group to contract this infection. 
Notwithstanding, there is still little evidence regarding 
IDU and HCV contamination risk factors in this specific 
population, especially among cocaine users that do not 
use other psychoactive substances. Aceijas & Rhodes 
reviewed data on HCV prevalence among IDUs worldwide 
and found reports of HCV prevalence rates of at least 
50% among IDUs in 49 countries or territories.27
Overall, the prevalence of HCV infection in the 
IDU population varies greatly around the world, with 
midpoint reports ranging from 9.8 to 97.4%.7 There is 
evidence suggesting that the variation in prevalence 
and incidence observed between different populations 
could be explained by differences in cultural and ethnical 
aspects associated with stigma, discrimination, risk 
behaviors and/or access to health care, services and 
preventive education.29 Also, differences in prevalence 
rates seem to be gender- and age-specific among 
different DUI populations.30 Moreover, HCV is one of the 
infections most commonly identified among drug users 
– a recent systematic review suggested that about 
10.0 million IDUs (range 6.0-15.2) were contaminated 
with HCV in 2010, which is 3.5 times higher than the 
estimate for HIV infection in the same population (2.8 
million; range 0.8-6.2 million).7
One interesting study called HCV Synthesis Project, 
which is also a meta-analysis of studies of HCV 
epidemiology and prevention in drug users worldwide, 
examined data from 127 studies of IDUs that reported 
HCV prevalence rates in relation to age or year since 
onset of drug injection. That study reported that, even 
within the group of young users (<25 years old), or 
within the group of recent users (<1-3 years of use), 
the reported prevalence of HCV infection was equal or 
higher than 70%. Moreover, the study suggested that 
there is a high risk of acquiring HCV shortly after onset 
of drug injection. This is very worrisome and may have 
implications for future prevention strategies, since 
recent drug users are less likely to search treatment 
and therefore receive educational and prevention 
information.30,31 
One study with cocaine users found that injecting 
cocaine users are more likely to have HCV infection 
than those who deny injection practice.32 Similarly to 
general IDUs, higher family income, tattooing, sharing 
drug paraphernalia, history of drug use for more than 
5 years, and daily use of substances of abuse were risk 
factors to HCV infection among cocaine users.32 There is 
also evidence that the sharing of materials for injection 
other than syringes/needles, like filters and rinse water, 
contribute substantially to the spread of hepatitis C 
among IDUs.33,34
Genotypes 1a and 3a predominate among IDUs, 
with genotype 3a being far more frequent in IDUs than 
in the general population.35,36 In a study with Brazilian 
cocaine users, subtype 1 was most frequently found 
in the sample (73.3%), although genotype 3 was also 
found (26.7%), especially in injecting cocaine users 
(13.3%).32 It is assumed that the presence of different 
genotypes can be due to characteristics such as the 
geography from which the infection was contracted, 
type of drug used (injectable or non-injectable), and 
multiple exposures to HCV infections. Genotype 3, for 
instance, is more common in European populations.
When comparing cocaine injection among heroin-
dependent volunteers, participants who had injected 
cocaine during the previous month had a nine-fold 
greater risk of being HCV-positive compared to non-
cocaine users and those who used cocaine by a non-
injecting route.37 In this same sample, the more 
frequently the participant used cocaine during the 
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previous month, the greater their risk of being HCV-
positive. This highlights the need for special care in 
relation to HCV in the primary attention of drug users 
when they also consume cocaine.
Several studies are showing a high prevalence of 
psychiatric comorbidities in IDUs.38-41 Even though we 
know that psychiatric comorbidities are very prevalent 
in drug users, it is very difficult to isolate the symptoms 
when the patient is in active use or with a short period 
of abstinence. Population studies show that the most 
prevalent disorders in this population are anxiety 
disorders, followed by mood disorders and personality 
disorders, especially antisocial personality disorders. 
Personality traits or disorders as well as cognitive 
deficits could be an important issue to be addressed 
in this population. Personality disorders, e.g. borderline 
and antisocial, are associated with a greater likelihood 
of sharing injection equipment.42 Heroin IDUs with 
cognitive deficits are more likely to have a history of 
hepatitis C infection, supporting the idea that cognitive 
factors may lead to increased risky behaviors and 
thus transmission of infections.43 Other personality 
trait disorders, such as negative temperament and 
disinhibition, impulsivity, sensation-seeking, novelty 
seeking and reward-sensitivity are frequently reported 
in drug users.43 In this sense, psychiatric disorders 
may occur before or during drug abuse and are also 
associated with physical comorbidity, including HCV 
infection, and its treatments.44
Taken together, existing estimates underline 
that HCV remains a great harm to the health of both 
injectors and former injectors, creating a substantial 
health burden worldwide.28 HCV-negative status may 
be representative of an established subgroup of safer 
injectors who have remained free of infection because 
of consistent safe injecting practices.45
HCV and non-injecting cocaine use
Research has mainly focused on injection drug use, 
but non-injecting cocaine users are also at greater risk 
of HCV infection.46 Several studies have reported higher 
HCV infection in this group in comparison to the general 
population, particularly among crack cocaine users.8,47 
HCV prevalence among crack users varies greatly, from 
1.4%48 to around 50%.36 Intranasal cocaine users are not 
considered a risk group per se, but they could hide a route 
of parenteral virus spread.49 Even taking into account 
that some of them may not have reported drug injection 
in the past, HCV prevalence is higher than expected.8 
Therefore, other potential HCV infection routes have 
been suggested among non-injecting cocaine users.
Sharing non-injection drug use paraphernalia is a 
plausible route for HCV transmission in this population.9 
HCV RNA has already been detected in crack pipes,50 in 
nasal secretions and drug-sniffing implements of HCV-
infected intranasal drug users,10,51 making this infection 
route biologically reasonable. Among crack users, oral 
burns or cuts are frequent, and sharing crack pipes 
is a common practice in the drug scene.52 Consistent 
with this, sharing a crack pipe has been associated with 
HCV infection among crack users.9,53,54 With regard to 
sharing snorting devices and HCV infection, evidence 
suggests an association.8,9 As inhaled cocaine users are 
not systematically tested, blood donor studies have 
raised most of the evidence.49,55,56 In a recent study 
with HCV-infected blood donors, intranasal cocaine 
use was an independent risk factor, and most of them 
(86%) reported shared use of snorting devices.49 
Additionally, a high level of nasal pathology can be 
detected in intranasal cocaine users, such as erosion in 
nasal mucosa, rhinitis, septum perforation, loss of nasal 
hairs, all of which can increase the infection risk.51
Sexual transmission of HCV is much less efficient 
than HBV and HIV.57 However, some sexual risk 
groups show increased HCV prevalence with no other 
parenteral risk factor reported.58,59 Other concomitant 
sexually transmitted diseases with genital erosive 
lesions or traumatic sexual intercourse seems to 
enhance sexual transmission of HCV.60 Indeed, 
multiple sexual partners, drug use in the course of 
sex, exchanging sex for drugs or money have been 
reported to increase the risk of HCV infection.47,61-63 
In fact, both crack and intranasal cocaine users show 
levels of high sexual risk behavior, especially the 
former.47,64 Sexually transmitted diseases are frequent 
among female crack cocaine users exchanging sex for 
drugs or money, as well as in those who have multiple 
sexual partners, making them a vulnerable group for 
HCV infection.64,65 Accordingly, among non-injecting 
cocaine users, women crack cocaine users have the 
highest prevalence rates of HCV infection, reaching 
almost 60% in some samples.47,65
Tattooing and piercing as risk factors for HCV 
infection have conflicting findings in the literature.66 The 
increase in risk infection seems to be related to high-
risk groups, when tattoos are applied in prison settings 
or by friends66 – both practices are commonplace 
among drug users.54 In addition, drug users are more 
likely not to receive tattoos or piercings in professional 
parlors, and the prevalence of these characteristics can 
reach more than 30% for tattoos and more than 40% 
for piercings.54,67
Collectively, these findings suggest that these non-
parenteral routes of HCV infection add a small risk 
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each one. Nonetheless, non-injecting cocaine users are 
exposed to multiple high-risk situations, placing them 
in a major group of risk.
Prevention
Many countries in Europe may not yet have invested 
sufficiently in studies or surveillance systems to guide 
HCV treatment and prevention policies for IDUs.68,69 
In other countries, such as Canada, decreases in HCV 
incidence were accompanied by increases in crack 
cocaine smoking, and decreases in syringe borrowing 
coincided with a scale-up of harm reduction programs.70
Despite the progress made in the development 
of HCV vaccines,71 we still do not have an effective 
vaccine. Primary prevention against hepatitis C focuses 
on reducing risks of infection through safe injections, 
and blood safety remains the best alternative to reduce 
morbidity and mortality.1
Page et al. recently reviewed some HCV prevention 
strategies. The results demonstrated that efforts to 
reduce exposure to HCV in people who inject drugs 
must incorporate reduction of sharing drug preparation 
equipment. Besides, tests to identify acute HCV in the 
“window period” may aid in prevention, because this 
is a period with high viremia, during which individuals 
may not know that they are positive and may have a 
high risk of HCV transmission.71
Significant advances have been made in preventing 
HIV infection among injectors, but we still know little 
about preventing hepatitis C. Both prevalence and 
incidence of hepatitis C can remain high among IDUs 
even in the context of widespread implementation 
of harm reduction programs.72 The main impact on 
prevention is a reduced risk of infection through sharing 
syringes and needles. This may be possible with the 
distribution of new and sterile needles and through 
orientation of individuals on the use of disinfected 
equipment for the manufacture and use of drugs,73 in 
addition to the promotion of interventions for abstinence 
from substance use. Indicated interventions include 
motivational techniques, contingency management, 
specialized outpatient clinics, support groups, harm 
reduction and, depending on the severity and associated 
risks, hospitalization.
Improvement in mental health conditions, 
including the treatment of psychiatric comorbidities 
and psychoeducation about the disorders, is also very 
important when considering prevention strategies for 
any health outcome among drug users. For example, 
both drug use and HCV infection have independently 
been associated with depression and suicidality.74,75 
When overlooking these high-risk groups, evidence 
suggests a high prevalence of comorbidities among 
drug users with HCV.76 In this sense, suicide ideation, 
psychological morbidity and other psychiatric symptoms 
have been shown to be associated with HCV status and 
with IFN-α treatment.75 In fact, suicide was the second 
most reported cause of death among a sample of HCV-
positive drug users in a 33-year follow-up study.76 
Therefore, special attention should be given to HCV-
positive users through prevention strategies and routine 
assessment as part of a comprehensive approach to 
prevention and care. 
The last strategy is to promote HCV treatment. 
Current therapeutic advances are transforming chronic 
HCV into a routinely curable disease. HCV detection 
combined with the availability of simple, well-tolerated 
treatment regimens77 is an alternative to reduce virus 
infection in substance users.
Studies covering prevention strategies in NIDUs are 
still scarce, probably due to the evidence of inconsistency 
on the main routes of transmission. It is known that 
warning about the risks of sexual transmission is an 
important measure, since this is a vulnerable population 
to unprotected sex and drugs used as currency. Bertoni 
et al. showed that a large proportion of women reported 
involvement in sex-for-drug exchanges.78
Hepatitis C prevention counselling and education 
are intended to increase knowledge of the disease, 
clarify perceptions about vulnerability to infection, 
and increase personal capacity for undertaking safer 
behaviors. As with syringe sharing, the sharing of 
drug preparation equipment was associated with lower 
perceived benefits of safer injecting but also with low 
self-efficacy to convince others to inject more safely. 
Interventions should aim to heighten awareness of the 
benefits of risk reduction, and to provide IDUs with the 
skills necessary to negotiate safer injection practices 
with their peers.79
Among illicit drug users attending inner city clinics 
in Canada, studies have observed a low uptake of HCV 
treatment, but a high willingness to receive therapy.80 
An increased focus on improving education about the 
long-term consequences of HCV and the availability 
of effective treatment are important components for 
expanding HCV treatment among illicit drug users.72 This 
means guidance on risk behavior, prevention of sexually 
transmitted diseases, interventions on violence and 
crime approach, plus psychoeducation about substance 
use disorders and psychiatric comorbidities such as mood 
disorders, anxiety disorders and personality disorders.
It is relevant to point out that some authors 
suggest that heroin and cocaine users with cognitive 
deficits are more likely to have a history of hepatitis 
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B and/or C infection, supporting the idea that 
cognitive factors may lead to higher rates of risky 
behaviors and thus transmission of infection.42,81 They 
suggest that identification and evaluation of cognitive 
impairment should be considered among individuals 
with substance use disorders. Individuals with such 
conditions who abuse drugs may be at an increased 
risk of infectious diseases and may struggle to succeed 
in treatment programs. The findings highlight the need 
for adaptations that can be made to this potentially 
large subpopulation of drug users. 
Conclusion
Evidence shows that cocaine use is associated with 
increased risk for HCV contamination. The main aspects 
that have been raised to explain this association are 
the main forms of administration of cocaine (injection, 
aspiration and inhalation) and other risky behaviors that 
are frequently perceived in these drug users. Injectable 
cocaine users seem to be more likely to contamination 
than users who do not inject drugs. However, because 
of the right prevalence of HCV in non-injecting cocaine 
users, evidence has been pointing to possibility of 
contamination through the sharing of drug paraphernalia 
other than syringes.
Other risk behaviors for contamination, like 
unprotected sex and tattooing, are also highly 
observed in this population. It is also important to 
consider that the use of cocaine leads to considerable 
immunosuppression, which also favors viral infections. 
Specific impairments in the immune system caused by 
cocaine use, such as an increased expression of NF-
κB, are also linked with HCV infection susceptibility, 
persistence and increased pathological effects. When 
we take this evidence into account, it seems apparent 
that cocaine users are a major risk group for HCV 
contamination. However, more studies are necessary in 
order to understand the specific risk factors of cocaine 
consumption in regards to HCV.
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